Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds

Guix, B.; Finestres, F.; Tello, J.; Palma, César; Martı́nez, Antonio; Guix, José-Ramón; Guix, R.

doi:10.1016/s0360-3016(99)00547-7

Cited by 177 publications

(197 citation statements)

References 16 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…Classic c brachytherapy requires complex software programs for treatment planning and calculation of dose distribution to obtain an individually adjusted dose distribution, but the dose distribution remains far from ideal, due to the penetrating nature of the photons, and a large number of sessions (30-40) are usually required. 6 The use of b radiation embedded in a tailor-made irradiation mould, such as the technique we describe here, appears able to override the drawbacks of classic radiotherapy. In fact, not only can the margin of irradiation be easily controlled by the present technique, but the dose-distribution curve obtained by beta particles (Fig.…”

Section: Discussionmentioning

confidence: 98%

“…Radiotherapy, using low-energy X-rays (£ 90 kVs) or electrons, and interstitial brachytherapy with c-ray emitting sources placed across the tumour volume, have both been used in clinical practice. 6 In this paper, we present a new treatment for BCC and of SCC. This consists of superficial radiotherapy, characterized by the use of a specially formulated, inert, synthetic resin containing radioactive b-emitting isotopes, which is able to adapt to skin surfaces without spreading beyond the tumour area, allowing accurate dose distribution and sparing of healthy tissue.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma

Sedda

Rossi

Cipriani

et al. 2008

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

SummaryBackground. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans. Various therapies are currently being used to treat these tumours including surgery, topical treatments and radiotherapy. We describe a new treatment for BCC and SCC. This consists of superficial radiotherapy, using synthetic resin containing a radioactive b-emitting isotope. The resin is applied to the lesion to perform a selective b-irradiation brachytherapy treatment. Methods. In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment. Results. In all treated cases, an apparent clinical remission occurred in approximately 3 months, and complete healing was obtained in 100% of the treated patients; in 82% of the cases, this occurred after a single application. No disfiguring scars or any side-effects were seen. After a follow-up of 20-72 months (mean 51 months), no clinical relapses were observed in the treated patients. Histological examination confirmed complete tumour regression. Conclusion. The results indicated that brachytherapy is an effective treatment for BCC and SCC.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma

Sedda

Rossi

Cipriani

et al. 2008

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…596 The other reported SCC recurrence occurred 23 months after high-dose rate brachytherapy with a 192 Ir surface mould and was a 4-cm tumour located on the frontal area. 597 No patients in this study developed regional or distant metastases after treatment.…”

Section: Brachytherapymentioning

confidence: 69%

“…Six studies (comprising 88 SCCs) reported recurrence after brachytherapy [592][593][594][595][596][597] (see Appendix 9 and Figure 44), giving a pooled average local recurrence of 5.2% (95% CI 1.6% to 10.5%; I 2 = 0%). Of these, four were prospective reports (35 SCCs) 592,594,595,597 and two (53 SCCs) were retrospective, 593,596 with varying follow-up periods from an average of 9.6 months 595 up to a median of 55 months.…”

Section: Brachytherapymentioning

confidence: 99%

See 1 more Smart Citation

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy

et al. 2015

View full text Add to dashboard Cite

Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds

Cited by 177 publications

References 16 publications

Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma

Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy

Contact Info

Product

Resources

About